Abstract
Diabetes mellitus (DM) is a condition with high blood sugar levels (hyperglycemia), which can have adverse effects on several organ systems. Commercial DM medications are used as therapy for people with DM type II; however, they have side effects that were attributed to high inhibitory effects on a-amylase enzymes. Therefore, new compounds with strong a-glucosidase inhibition and low a-amylase inhibition need to be developed. Cinnamic acid derivatives such as cinnamamides have been shown to possess a-glucosidase inhibitory activity. Bioactive molecules containing a hydrazide moiety, such as isoniazid (INH), are reported to have a broad spectrum of biological activity. Herewith we report the synthesis of a new cinnamamide as a hybridization of trans-cinnamate and INH molecules, namely (E)-N'-(3-(4-bromophenyl)acryloyl)isonicotinohydrazide (5), and its inhibitory activity against a-amylase enzyme. The synthesis of this compound was carried out by the Shiina method, and a yield of 59% was obtained. Cinnamamide 5 has weak a-amylase inhibitory activity than acarbose with IC50 values of 109.8 and 6.37 µM, respectively.
| Original language | English |
|---|---|
| Article number | 020029 |
| Journal | AIP Conference Proceedings |
| Volume | 3071 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 11 Apr 2024 |
| Event | 5th International Seminar on Chemistry, ISoC 2022 - Surabaya, Indonesia Duration: 12 Oct 2022 → 13 Oct 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'a-Amylase inhibitory activity of (E)- N' -(3-(4-bromophenyl)acryloyl)isonicotinohydrazide'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver